Printer Friendly

Eidogen-Sertanty licenses TIP technology to FDA's National Center for Toxicological Research.

M2 EUROPHARMA-(C)1999-2009 M2 COMMUNICATIONS

8 December 2009 - US-based computational drug discovery solutions provider Eidogen-Sertanty Inc said today it has licensed its Target Informatics Platform (TIP) to the US Food and Drug Administration's (FDA) National Center for Toxicological Research (NCTR).

Under the terms of the license, scientists within NCTR will have access to the complete TIP structural knowledgebase via onlineTIP as well as access to the TIP/Workgroup technology for internal research. The company will also participate in several NCTR-led projects including the multi-year PADRE project (MAQC-IV), which is focusing on the modelling of drug-protein interactions to identify new genetic variations that may lead to serious adverse drug reactions.

Eidogen-Sertanty's CEO Dr. Steven Muskal said that the company is looking forward to having a positive impact in the FDA's effort to predict serious adverse drug reactions at the individual patient level.

COPYRIGHT 2009 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Dec 8, 2009
Words:142
Previous Article:Celgene reports results from study of REVLIMID in patients with smoldering multiple myeloma.
Next Article:TSO3 files with Health Canada for STERIZONE 125L+ Sterilizer.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters